Clinical trial
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
NCT01687998 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
- Lead sponsor
- Eli Lilly and Company
- Phase
- Phase 3
- Overall status
- Terminated
- Start date
- October 31, 2012
- Completion date
- July 31, 2016
- Enrollment
- 12,092 (actual)
- Sites
- 444
Conditions
As the registry lists them; a condition with its own page is linked.